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Abstract
The causative effect of GM-CSF produced by cardiac fibroblasts to development of heart failure 
has not been shown. We identified the pathological GM-CSF-producing cardiac fibroblast subset 
and the specific deletion of IL-17A signaling to these cells attenuated cardiac inflammation and 
heart failure. We describe here the CD45−CD31−CD29+mEFSK4+PDGFRα+Sca-1+periostin+ 
(Sca-1+) cardiac fibroblast subset as the main GM-CSF producer in both experimental 
autoimmune myocarditis and myocardial infarction mouse models. Specific ablation of IL-17A 
signaling to Sca-1+periostin+ cardiac fibroblasts (PostnCreIl17rafl/fl) protected mice from post-
infarct heart failure and death. Moreover, PostnCreIl17rafl/fl mice had significantly fewer GM-CSF-
producing Sca-1+ cardiac fibrob-lasts and inflammatory Ly6Chi monocytes in the heart. Sca-1+ 
cardiac fibroblasts were not only potent GM-CSF producers, but also exhibited plasticity and 
switched their cytokine production profiles depending on local microenvironments. Moreover, we 
also found GMCSF-positive cardiac fibroblasts in cardiac biopsy samples from heart failure 
patients of myocarditis or ischemic origin. Thus, this is the first identification of a pathological 
GMCSF-producing cardiac fibroblast subset in human and mice hearts with myocarditis and 
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ischemic cardiomyopathy. Sca-1+ cardiac fibroblasts direct the type of immune cells infiltrating 
the heart during cardiac inflammation and drive the development of heart failure.
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Introduction
Heart failure is a global public health issue with high morbidity and mortality rates, affecting 
about 26 million people worldwide [1]. The heart failure survival rate is 50% after 5 years 
and 10% after 10 years in USA [2, 3]. In contrast to other common cardiovascular diseases, 
heart failure prognoses have shown only modest improvement [4]. The pathophysiology of 
heart failure is complex and could be triggered by direct injury to the myocardium, such as 
coronary artery disease and myocardial infarction (MI), or an inflammatory disease state 
such as myocarditis that leads to inflammatory dilated cardiomyopathy (DCMi) [5–9].
Studies from our lab and others on both myocarditis and MI mouse models revealed that 
interleukin (IL)-17A, a hallmark cytokine of T helper (Th) 17 cells, plays an important role 
during post-injury cardiac inflammation and drives the development of heart failure [10, 11]. 
We found that IL-17A signaling to cardiac fibroblasts, not to immune cells, is essential in 
the development of heart failure in an experimental autoimmune myocarditis (EAM) mouse 
model [12]. We showed that IL-17A induced cardiac fibroblasts to produce myelotropic 
cytokines and chemokines, such as granulocyte macrophage colony-stimulating factor (GM-
CSF) and C-C motif chemokine ligand 2 (CCL2, also known as monocyte chemoattractant 
protein-1), to modulate the immune responses during cardiac inflammation [12]. Others 
have also reported that cardiac fibroblasts produce GM-CSF and drive the pathology in 
Kawasaki disease and MI [13, 14].
Despite being often considered as a single homogenous cell population, cardiac fibroblasts 
are an ambiguously defined cluster of heterogeneous cell populations [15–17]. During 
embryonic development epicardial cells undergo an epithelial-tomesenchymal transition to 
become epicardial-derived cells, which penetrate the myocardium to become cardiac 
fibroblasts [18–20]. Some epicardial-derived cells stay at the sub-epicardial region as 
mesenchymal stem cells [21–23]. These mesenchymal stem cells remain quiescent and 
differentiate into cardiac fibroblasts only in response to injury [22, 23]. Another possible 
source of cardiac fibroblasts are fibrocytes, which are monocyte-like collagen-producing 
cells derived from bone marrow [24]. Fibrocytes circulate in the periphery and accumulate in 
tissues where injury occurs [25–28]. Fibrocytes have been extensively studied in lung 
fibrosis and skin wound healing, but not in cardiac remodeling processes [29–33].
In this study, we set to investigate whether all cardiac fibrob-lasts are able to produce GM-
CSF or whether a specialized cardiac fibroblast subset is responsible for this pathogenic 
pathway that drives heart failure in both EAM and MI mouse models. We identified the main 
GM-CSF producers during cardiac inflammation to be a specific subset of cardiac 
fibroblasts, the stem cell antigen-1 positive (Sca-1+) cardiac fibroblasts characterized by the 
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marker profile CD45−CD31−CD29+mEF-SK4+PDGFRα+Sca-1+periostin+. Specific 
ablation of IL-17A signaling to Sca-1+ cardiac fibroblasts protected mice from post-infarct 
heart failure and resulted mortality. Moreover, Sca-1+ cardiac fibroblasts exhibited plasticity 
and produced GM-CSF and CCL2 in response to a Th17 microenvironment, while they were 
able to be repolarized to secrete eotaxin when placed in a Th2 microenvironment. We also 
found a similar subset of GM-CSF-producing cardiac fibroblasts identified by the marker 
profile CD45−CD31−CD29+PDGFRα+ in biopsies from heart failure patients of both 
myocarditis and ischemic origin. Thus, Sca-1+ cardiac fibroblasts are the specialized cardiac 
fibroblast subpopulation that produces GM-CSF and drives heart failure.
Results
Sca-1+ cardiac fibroblasts are potent GM-CSF-producers during cardiac inflammation
We described previously that cardiac fibroblasts produce GM-CSF in response to IL-17A 
during myocarditis [12]. To determine whether a specific cardiac fibroblast subset produces 
GM-CSF and the relative contribution to the overall cardiac GM-CSF production during 
myocarditis, we classified cardiac fibroblasts based on their surface marker expressions (Fig. 
1A) [34]. The first subset was gated as CD45−CD31−CD29+mEF-SK4+PDGFRα+Sca-1+ 
(depicted further as Sca-1+) cardiac fibroblasts, and the second subset was gated as 
CD45−CD31−CD29+mEF-SK4+Sca-1− (depicted as Sca-1−) cardiac fibroblasts. As another 
possible source of cardiac fibroblasts during cardiac inflammation, fibrocytes were analyzed 
as the third subset and gated as CD45+CD31−CD11b+CD34+CXCR4+CollagenI+. All 
Sca-1+ cardiac fibroblasts expressed the cardiac fibroblast marker, platelet-derived growth 
factor receptor alpha (PDGFRα), while cells expressing another fibroblast marker CD90 (as 
known as thymus cell antigen-1) were found in both Sca-1+ and Sca-1− cardiac fibroblasts 
(Fig. 1A). We examined the numbers of cardiac fibroblast subsets in na¨ıve hearts (day 0) 
and in the diseased hearts on days 14 and 21 of EAM (Fig. 1B). We observed a significant 
increase in the number of Sca-1+ cardiac fibroblasts on day 21 of EAM, but not on day 14 
(Fig. 1B, C). In contrast, the number of Sca-1− cardiac fibroblasts decreased on day 14 and 
remained diminished on day 21 (Fig. 1B, C). Very few fibrocytes were found in the na¨ıve 
heart; the number of fibrocytes increased significantly on day 14 and continued to increase 
through day 21 of EAM (Fig. 1B, C).
We examined the GM-CSF production at day 21 of EAM and revealed that GM-CSF-
positive cardiac fibroblasts were mostly Sca-1+ cardiac fibroblasts, while GM-CSF 
production by the other two cardiac fibroblast subsets was negligible (Fig. 1D). Using t-
distributed stochastic neighbor embedding (t-SNE) clustering algorithm, we confirmed that 
most of GM-CSF-positive cardiac fibroblasts were in the cluster of Sca-1+ cardiac 
fibroblasts (Fig. 1E). To establish the relative contribution of Sca-1+ cardiac fibroblasts to 
the total GM-CSF production during EAM, we analyzed GM-CSF production by all cell 
types in the heart (Fig. 1F,G). Endothelial cells produced negligible amount of GM-CSF 
(Supporting Information Fig. 1A) and the number of endothelial cells was not changed 
during EAM development (Supporting Information Fig. 1B). On the other hand, the number 
of infiltrating leukocytes increased dramatically during EAM development (Supporting 
Information Fig. 1C), among which, lymphocytes and myeloid cells produced substantial 
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amounts of GM-CSF (Supporting Information Fig. 1A). However, the major GM-CSF 
producers were still Sca-1+ cardiac fibroblasts among all GM-CSF-positive cardiac cells 
(Fig. 1F), and Sca-1+ cardiac fibroblasts represented over 50% of GM-CSF-positive cardiac 
cells at day 21 of EAM (Fig. 1G). Thus, Sca-1+ cardiac fibroblasts were not only active GM-
CSF producers, but also the major source of GM-CSF during cardiac inflammation.
In order to determine whether the increase of GM-CSF-positive Sca-1+ cardiac fibroblasts is 
specific to cardiac inflammation, we compared GM-CSF-positive Sca-1+ cardiac fibroblasts 
from mice with EAM to that from mock-immunized mice (CFA alone) on day 21 post-
immunization. Both the frequency and the number of GM-CSF-positive Sca-1+ cardiac 
fibroblasts were significantly higher in EAM hearts compared to that in the hearts of the 
mock-immunized mice (Fig. 1H). In addition, both the frequency and the number of GM-
CSF-positive Sca-1+ cardiac fibroblasts were significantly lower in Il17ra−/− mice compared 
to that in the WT mice on day 21 of EAM (Fig. 1I). Therefore, GM-CSF production by 
Sca-1+ cardiac fibroblasts is specific to cardiac inflammation and dependent on IL-17A 
signaling in EAM mouse model.
Sca-1+ cardiac fibroblasts are potent cytokine producers and are plastic to environment 
changes
The dominant role of Sca-1+ cardiac fibroblasts as the major GMCSF producers during 
EAM led us to investigate whether Sca-1+ cardiac fibroblasts are capable of expressing other 
cytokines and chemokines during cardiac inflammation. We FACS-sorted Sca-1+ and Sca-1− 
cardiac fibroblasts on day 21 of EAM and assessed the mRNA expression levels of various 
cytokines and chemokines. We detected significantly enriched mRNA expression levels of 
Csf2, Ccl2, Cxcl10 and Ccl11 in sorted Sca-1+ cardiac fibroblasts compared to whole heart 
transcripts and sorted Sca-1− cardiac fibrob-lasts (Fig. 2A). In addition to the expression of 
these immune mediators in sorted Sca-1+ cardiac fibroblasts, we detected significantly 
enriched mRNA expression levels of periostin (Postn) (Fig. 2A). Periostin is known to be 
upregulated in activated cardiac fibroblasts upon cardiac injury [34, 35].
Next, we isolated CD45−CD31−Sca-1+ cardiac cells from na¨ıve adult mouse hearts and 
examined their responses to signature Th cytokines. Sca-1+ cardiac fibroblasts expressed 
Csf2 and Ccl2 mRNA in response to IL-17A, while IL-13 and interferon gamma (IFN-γ) 
induced Sca-1+ cardiac fibroblasts to express Ccl11 and Cxcl10 mRNA respectively (Fig. 
2B). The ability of Sca-1+ cardiac fibroblasts to express different cytokines in response to 
different signature Th cytokines led us to investigate whether Sca-1+ cardiac fibroblasts 
exhibit plasticity, i.e. previously IL-17A-treated Sca-1+ cardiac fibroblasts are capable to 
respond to signatureTh2 stimuli and start to produce eotaxin. To answer this question, we 
isolated Sca-1+ cardiac fibroblasts from CCL2-mCherry reporter mice, these cells express 
mCherry following expression of CCL2 [36]. The majority of Sca-1+ cardiac fibroblasts 
became mCherry-positive after culturing in the Th17 microenvironment (Fig. 2C). We used 
the combination of IL-17A and TNF-α as the representative Th17 microenvironment, as our 
lab and others have previously reported that TNF-α synergizes with IL-17A in the 
production of IL-17A-induced genes [12, 37]. After culturing CCL2-mCherry Sca-1+ 
cardiac fibroblasts in the Th17 microenvironment for 3 days, we FACS-sorted mCherry-
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positive cells on day 3 and re-cultured them in the Th2 microenvironment for another three 
days (Fig. 2D).
After three days of culture in the Th17 microenvironment, Sca-1+ cardiac fibroblasts 
expressed Ccl2 and Csf2 mRNA, but not Ccl11 mRNA (Fig. 2E). After FACS sorting and 
reculturing in Th2 microenvironment, we observed reduced levels of Ccl2 and Csf2 mRNA 
expression in the previous mCherry-positive cells, while Ccl11 mRNA expression was 
upregulated (Fig. 2E). Protein levels of secreted CCL11 and GM-CSF in the culture 
supernatant followed the same trend (Fig. 2F). These results clearly demonstrated that 
Sca-1+ cardiac fibroblasts are plastic and capable to be repolarized in response to changes in 
the microenvironments.
IL-17A induces GM-CSF production in Sca-1+ cardiac fibroblasts through activation of NF-
κB and NFAT2
Next, we investigated the signaling pathways that participate in the induction of GM-CSF 
production by Sca-1+ cardiac fibrob-lasts. We performed phospho-flow cytometry on Sca-1+ 
cardiac fibroblasts cultured in different Th microenvironments. It was previously reported in 
T lymphocytes, that synergistic activation of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) and Nuclear factor of activated T-cells 2 (NFAT2, as known as 
NFATc1) was observed during GM-CSF transcription activation [38, 39]. Few unstimulated 
Sca-1+ cardiac fibroblasts were positive for phosphorylated p65 (RelA, component of NF-
κB) (p-p65) and NFAT2, while about half of Sca-1+ cardiac fibrob-lasts became p-
p65+NFAT2+ under Th17 conditions (Fig. 3A). Moreover, GM-CSF was detected in most of 
these p-p65+NFAT2+ Sca-1+ cardiac fibroblasts (Fig. 3A).
To further investigate the differences in signaling pathways under different Th conditions, 
we examined the protein levels and the phosphorylation state of various signaling molecules. 
We detected increased phosphorylation levels of p65, Signal transducer and activator of 
transcription 3 (Stat3) and Erk1/2 under both Th17 and Th2 conditions. Stat6 was only 
phosphorylated under Th2 conditions (Fig. 3B). We isolated the nuclear fraction from the 
stimulated cells and found that p65 nuclear translocation took place specifically under Th17 
conditions (Fig. 3C), despite the fact that p65 was phosphorylated under both conditions 
(Fig. 3B). In contrast, Stat6 nuclear translocation only occurred under Th2 conditions (Fig. 
3C). Thus, we revealed that Th17-induced GMCSF production by Sca-1+ cardiac fibroblasts 
is associated with synergistic activation of NF-κB and NFAT2. The balance between NF-κB/
NFAT2 and Stat6 activations determines the functional plasticity of Sca-1+ cardiac 
fibroblasts during cardiac inflammation between Th17 and Th2 microenvironments.
IL-17A signaling ablation leads to less GM-CSF+Sca-1+ cardiac fibroblasts and reduced 
post-MI death
To test the pathological relevance of Sca-1+ cardiac fibroblasts in ischemic heart failure 
development, we induced MI in mice via ligation of left anterior descending coronary artery. 
In line with our findings in the myocarditis model, Sca-1+ cardiac fibroblasts produced GM-
CSF and CCL2 2 days post-MI (Fig. 4A, B). A previous study showed that IL-17A ablation 
is protective in MI mouse model [11]. In our study, we found a similar protection from MI in 
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the IL-17A receptor (IL-17RA) knockout (Il17ra−/−) mice (Fig. 4C, D). The survival rate of 
Il17ra−/− mice at day 28 post-MI was 88 %, compared to 50 % of WT mice (Fig. 4C). We 
also observed reduced infarct size in Il17ra−/− mice at day 28 post-MI (Fig. 4D, E). We 
found significantly fewer GM-CSF-positive Sca-1+ cardiac fibroblasts in Il17ra−/− mice 
compared to WT mice (Fig. 4F). Therefore, we showed the ablation of IL-17A signaling led 
to less GM-CSF-positive Sca-1+ cardiac fibroblasts, reduced infarct size and improved post-
MI survival.
IL-17RA ablation in GM-CSF+Sca-1+Periostin+ cardiac fibroblasts attenuates post-MI heart 
failure
To test the requirement of IL-17A signaling specifically to GM-CSF-positive Sca-1+ cardiac 
fibroblasts in the development of post-MI heart failure and death, we searched for cardiac 
fibroblast specific Cre-expressing mice. Sca-1Cre mice were not available to us; however, we 
found Sca-1+ cardiac fibroblasts expressed high levels of periostin (Fig. 2A). Periostin is a 
matrixcellular protein firstly identified in periosteum [40], but stands out as a specific 
marker for activated cardiac fibroblasts [41]. Moreover, we found that most GM-CSF-
positive Sca-1+ cardiac fibroblasts were positive for periostin (GFP) in PostnCre/eGFP 
reporter mice (Fig. 5A). Thus, we crossed Il17rafl/fl mice to PostnCre/eGFP mice to 
specifically ablate IL-17RA in periostin-positive cells (PostnCreIl17rafl/fl mice). Specific 
ablation of IL-17RA in periostin+ cardiac fibroblasts limited the infarct region to a restricted 
area right below the occlusion site, whereas the infarct expanded to the whole left ventricles 
of the control mice (Fig. 5B). The infarct size of PostnCreIl17rafl/fl mice (labeled as 
PostnIL−17RAKO in the figure) at day 7 post-MI was significantly smaller than that of the 
controls (Fig. 5C). The survival rate at day 28 post-MI was also improved by the specific 
ablation of IL-17RA in periostin+ cardiac fibroblasts (Fig. 5D). The number of GM-CSF
+Sca-1+ cardiac fibroblasts was significantly reduced in infarcted PostnCreIl17rafl/fl hearts 
compared to control animals (Fig. 5E). In addition, we found that both the frequency and the 
number of Ly6Chi inflammatory monocytes were significantly lower in the hearts of 
PostnCreIl17rafl/fl mice compared to control mice (Fig. 5F, G, gating strategy for Ly6Chi 
inflammatory monocytes illustrated in Supporting Information Fig. 2). We showed before 
that these Ly6Chi inflammatory monocytes were correlated with cardiac fibrosis and heart 
failure development [12]. These results demonstrated that the ablation of IL-17A signaling 
to GM-CSF-expressing Sca-1+ (periostin+) cardiac fibroblasts led to reduced GM-CSF 
production by Sca-1+ cardiac fibroblasts, decreased number of Ly6Chi inflammatory 
monocytes, reduced infarct size and improved post-MI survival.
GM-CSF+ cardiac fibroblast subset in human’s hearts exhibits similar functional plasticity
Next, we examined whether GM-CSF and other cytokines and chemokines are produced by 
a similar cardiac fibroblast subset in human cardiac fibroblasts, and whether these cardiac 
fibrob-lasts also exhibit similar functional plasticity. First, we acquired human primary 
cardiac fibroblasts isolated from the left ventricles of healthy donors from Cell Application, 
Inc. [42–44] and characterized them by flow cytometry. We detected three populations in 
these human cardiac fibroblasts based on CD29 and cKit expression, i.e. CD29+cKit+, 
CD29+cKit−, and CD29−cKit−cells (Fig. 6A). Using t-SNE clustering algorithm, we 
observed three automatically formed clusters (Fig. 6B), which matched the manually gated 
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populations (Fig. 6A). Mesenchymal stem cell markers, CD29, CD73 and CD105 were co-
expressed by both CD29+cKit+ and CD29+cKit− cells, while CD90 was expressed in 
CD29+cKit+ cells and some CD29+cKit− cells. PDGFRα was expressed at intermediate 
levels by all three subsets, while cKit and another cardiac fibroblast marker, discoidin 
domain receptor 2 (DDR2), were co-expressed only in CD29+cKit+ cells. GM-CSF was 
expressed by CD29+cKit+ and CD29+cKit− cells, but not CD29−cKit− cells (Fig. 6C). 
Further analysis on the cytokine expression profiles of these human cardiac fibroblasts 
revealed that IL-17A induced the mRNA expression of CCL2 and CSF2, whereas increased 
mRNA expression levels of eotaxins CCL11, CCL24 and CCL26 was detected after IL-13 
stimulation (Fig. 6D). When Th microenvironments were changed from Th17 to Th2 
conditions, we detected reduced CSF2 mRNA expression, while CCL11, CCL24 and 
CCL26 mRNA expression levels were upregulated (Fig. 6E). The protein concentration of 
secreted GM-CSF and CCL11 in the culture supernatant followed the same trend 
(Supporting Information Fig. 3). Therefore, human GM-CSF-expressing cardiac fibroblasts, 
identified by markers CD29, PDGFRα, CD73 and CD105, exhibit similar functional 
plasticity to be repolarized as mice GM-CSF-expressing cardiac fibroblasts.
Human cardiac fibroblasts from heart failure patients produce GM-CSF and CCL2
To confirm the data from human cardiac fibroblast in vitro culture, we examined biopsy 
samples from patients with myocarditis and ischemic cardiomyopathy undergoing 
implantation of left ventricular assist devices. Using flow cytometry, we identified the 
cardiac fibroblasts in these biopsy samples as CD45−CD31−CD29+PDGFRα+ (Sca-1 is not 
expressed in humans) cells (Fig. 7A). These PDGFRα+ cardiac cells expressed the same set 
of mesenchymal cell markers, including CD29 and PDGFRα, similar to the Sca-1+ 
(PDGFRα+) cardiac fibroblasts we have described in mice and the in vitro cultured human 
cardiac fibroblasts. Moreover, we showed that PDGFRα+ cells were source of GM-CSF or 
CCL2, whereas PDGFRα− cells were negative for GM-CSF and CCL2 staining (Fig. 7A). 
We observed strong GM-CSF production in human PDGFRα+ cardiac fibroblasts from 
myocarditis patients (Fig. 7B). CCL2 was identified only in one patient (Fig. 7B). In 
contrast, in biopsies from ischemic patients, we observed CCL2-positive PDGFRα+ cardiac 
fibroblasts in three out of five patients, and GM-CSF-positive PDGFRα+ cardiac fibroblasts 
were found in four out of five patients (Fig. 7C). All cardiac samples evaluated by flow 
cytometry were acquired when left ventricular assist device was implanted due to severe 
heart failure. The histology evaluation of the samples reviled advanced fibrotic changes with 
ongoing inflammation (Supporting Information Fig.4). Thus, we identified GM-CSF- and 
CCL2-exprssing PDGFRα+ cardiac fibroblasts in both myocarditis and ischemic heart 
failure patients, however, the finding was not consistent for all ischemic patients.
Discussion
For decades cardiac fibroblasts were mostly known as extracellular matrix protein producers 
[45, 46]. We identified a specific cardiac fibroblast subset that drives the development of 
heart failure as potent producers of inflammatory cytokines and chemokines. This cardiac 
fibroblast subset, defined as CD45−CD31−CD29+mEF SK4+PDGFRα+Sca-1+periostin+ 
(Sca-1+) cardiac fibroblasts, are capable of producing various cytokines and chemokines, 
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such as GM-CSF and CCL2 during the progression of cardiac disease from inflammation to 
heart failure. The number of Sca-1+ cardiac fibroblasts increased dramatically in both 
myocarditis and MI mouse models, and the GM-CSF-expressing Sca-1+ cardiac fibroblasts 
represented over 50% of total GM-CSF-expressing cells in the diseased hearts. The GM-
CSF production by cardiac fibroblasts was first shown by us in the EAM mouse model [12], 
and later by another two groups in Kawasaki disease and MI models [13, 14]. However, it 
remained elusive whether all cardiac fibroblasts are responsible for the production of GM-
CSF. Here we further characterized the heterogeneous cardiac fibroblast population and 
found GM-CSF production only in Sca-1+ cardiac fibroblasts among all cardiac resident 
cells. Moreover, we established that the production of GM-CSF by Sca-1+ cardiac 
fibroblasts is a general mechanism for multiple cardiac diseases, including myocarditis and 
myocardial infarction.
In addition to GM-CSF, Sca-1+ cardiac fibroblasts also produce other cytokines and 
chemokines, including CCL2, CXCL10 and eotaxin during cardiac inflammation. The 
capability of Sca-1+ cardiac fibroblasts to produce different cytokines and chemokines 
revealed the complexity of the local cytokine microenvironments in cardiac inflammation. 
Ablating IL-17A or IL-4 protected mice from the development of DCMi, while removing 
IFN-γ or IL-13 led to more severe diseases in the EAM mouse model [10, 12, 47–50]. Thus, 
maintaining the right balance among different Th-directed cytokines is critical in preventing 
or limiting the progression of cardiac diseases to heart failure. We recently reported in a 
model of eosinophilic myocarditis that cardiac fibroblasts are potent producers of eotaxin 1 
(CCL11), which is the main chemokine that regulates eosinophil trafficking to the heart [51]. 
In this study, we used the Sca-1+ cardiac fibroblasts from CCL2-mCherry reporter mice to 
demonstrate that the previous GM-CSF- and CCL2-expressing Sca-1+ cardiac fibroblasts are 
capable of switching to CCL11 producers after repolarization from Th17 to Th2 conditions. 
Moreover, we demonstrated here that conditional knockout mice that cannot receive IL-17A 
signaling to periostin-expressing cardiac fibroblasts, that are mostly GM-CSF-producing 
Sca-1+ cardiac fibroblasts, have reduced frequency and number of inflammatory Ly6Chi 
monocytes infiltrating the hearts. Sca-1+ cardiac fibroblasts thus have a decisive role in what 
immune cells will traffic to the heart and by affecting myeloid populations these cells drive 
heart failure development. Therefore, Sca-1+ cardiac fibroblasts are potential therapeutic 
targets to manipulate the balance of local cytokines and chemokines to manipulate the 
recruitment of immune cells during the inflammatory phase of myocarditis or myocardial 
infarction.
The induction of GM-CSF production in T cells involves the activation of both NF-κB and 
NFAT2 [38, 39, 52–57]. The activation of NF-κB pathway was also reported in TNF-α- and 
IL-17A-induced activation of synovial fibroblasts and endothelial cells [58, 59]. In our 
study, we revealed that the same synergistic activation of NF-κB and NFAT2 promoted 
IL-17A-induced GM-CSF production in Sca-1+ cardiac fibroblasts. However, we did not 
detect the activation of p38 mitogen-activated protein kinase (MAPK) pathway that was 
previously reported in TNF-α-induced GM-CSF production [60]. We also found Stat6 
activation directed the signaling pathways in Th2 conditions. These results suggest that the 
balance between NF-κB/NFAT2 and Stat6 activations determine the functional plasticity of 
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Sca-1+ cardiac fibroblasts and manipulating the activation balance in Sca-1+ cardiac 
fibroblasts could be a potential therapeutic strategy.
In the MI model, both IL-17A [11] and GM-CSF [61] were shown to be pathogenic and 
promote the development of heart failure. GM-CSF was also recently reported to act locally 
and distally after onset of MI to generate and recruit inflammatory cells [14]. We connected 
the two pathogenic factors, IL-17A and GMCSF, through the Sca-1+ cardiac fibroblast 
subset, which responds to IL-17A to produce GM-CSF. We detected significantly fewer 
GMCSF-positive Sca-1+ cardiac fibroblasts in infarcted Il17ra−/− mice compared to 
infarcted WT mice. The reduction in the number of GM-CSF-positive Sca-1+ cardiac 
fibroblasts also correlates to the reduction of infarct size and improvement of post-MI 
survival rate of infarcted Il17ra−/− mice.
The co-expression of periostin, a marker of activated cardiac fibroblasts [34, 41], by most 
GM-CSF-positive Sca-1+ cardiac fibroblasts enabled us to specifically ablate IL-17A 
signaling to GM-CSF-expressing Sca-1+ cardiac fibroblasts through PostnCreIl17rafl/fl mice. 
The specific deletion of IL-17RA in periostin+ cardiac fibroblasts resulted in reduced 
number of GM-CSF-positive Sca-1+ cardiac fibroblasts and this reduction correlates with 
smaller infarct size and improved post-MI survival rate. It has been recently reported that the 
ablation of periostin+ cardiac fibroblasts prevents adverse cardiac remodeling after MI [62], 
however, the mechanism behind the cardiac remodeling driven by periostin+ cardiac 
fibroblasts was not stated. Based on our results we speculate that the mechanism could have 
been the deletion of GM-CSF-expressing cardiac fibroblasts since we demonstrated that the 
pathological GM-CSF-expressing Sca-1+ cardiac fibroblasts are periostin-positive.
To confirm our findings in mice, we examined both in vitro cultured human primary cardiac 
fibroblasts and human heart failure patient endomyocardial biopsy samples for similar GM-
CSF-expressing cardiac fibroblast subset. We characterized the human primary cardiac 
fibroblasts and found similar GM-CSF-expressing cardiac fibroblasts that express human 
mesenchymal stem cell markers, including CD29, CD73 and CD105 [63–65]. These cardiac 
fibroblasts are potent cytokine producers and exhibit similar functional plasticity in response 
to different microenvironments similar to the mouse Sca-1+ cardiac fibroblasts. Moreover, 
GM-CSF- and CCL2-expressing cardiac fibroblasts were also found in the cardiac biopsy 
samples from myocarditis and ischemic heart failure patients. In endomyocardial biopsies 
from myocarditis patients, most PDGFRα+ cells expressed GM-CSF. However, in 
endomyocardial biopsy samples from ischemic heart failure patients, PDGFRα+ cells were 
mostly positive for CCL2, whereas, GM-CSF staining pattern was not consistent. The 
patients in our cohort were biopsied when they received left ventricular assist device for 
severe heart failure. Some patients were acute, like myocarditis patient number four, who 
had giant cell myocarditis and died a few days later. This patient had pronounced production 
of GM-CSF and CCL2 by PDGFRα+ cardiac fibroblasts and quite a substantial amount of 
ongoing inflammation was observed together with ongoing fibrosis. Most other patients 
were chronic with histological changes indicating fibrosis with ongoing mild to moderate 
inflammation in the heart. Further study is needed to make a conclusion on the role of 
fibroblasts secreting GM-CSF and CCL-2 in the pathogenesis of human myocarditis and 
ischemic cardiomyopathy.
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The Sca-1+ cardiac fibroblasts we identified here might overlap with previously described 
Sca-1+ cardiac progenitor cells in previous mouse studies, as they share common markers 
including CD29, Sca-1 and PDGFRα [34, 66–69]. Although Sca-1 is not expressed in 
humans, we found the human GM-CSF-expressing cardiac fibroblasts were positive for 
PDGFRα and also multiple mesenchymal stem cell markers that were described previously, 
including cKit, CD29, CD73 and CD105 [63–65]. The expression of CD29, CD73 and 
CD105 indicates their mesenchymal origin and c-Kit marked their stem cell like properties 
and potential to differentiate to other cell types [63]. The cytokine repolarization 
experiments with primary human cardiac fibroblasts suggested that, just like the mouse 
Sca-1+ cardiac fibroblasts, these human cardiac fibroblasts are also plastic and able to 
repolarize based on the changes in their microenvironment.
Materials and methods
Patients
We obtained endomyocardial biopsy samples from the apex of the left ventricle of patients 
with advanced heart failure undergoing implantation of left ventricular assist devices at the 
Texas Heart Institute. Informed consent was obtained from human subjects and the study 
protocol was approved by the Committee for the Protection of Human Subjects (University 
of Texas Health Science Centre at Houston. IRB # HSC-MS-05–0074) as previously 
described [70]. Heart samples were preserved frozen in liquid nitrogen (−196°C) and kept at 
−80°C in the tissue bank at the Texas Heart Institute, Houston, TX. Patient’s information of 
all samples was processed with random non-linked code relabeling in a database at the time 
of preservation. Aliquots of the samples were shipped frozen and processed in our lab for 
flow cytometry.
Mice
WT BALB/cJ mice (6–10 weeks old, JAX000651) and WT C57BL/6J mice (8–12 weeks 
old, JAX000664), Ccl2fl/fl-mCherry (Ccl2-RFPflox, JAX016849) [36] mice were purchased 
from the Jackson Laboratories (Bar Harbor ME). Il17ra−/− mice [71] on the BALB/c 
background were provided by Amgen Inc. (Thousand Oaks, CA) and Dr. J. Kolls 
(Children’s Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA). Il17rafl/fl 
mice [72] were provided on the C57BL/6 background by Dr. Ari Waisman (Institute für 
Molekulare Medizin Mainz, Germany) and PostnCre/eGFP mice [73] were provided on the 
C57BL/6 background by Dr. Simon Conway (Indiana University School of Medicine, 
Indianapolis, IN). Mice used for EAM model in this study were on the BALB/c background 
and mice used for MI model were on either the BALB/c background (Il17ra−/− mice) or the 
C57BL/6 background (Il17rafl/fl mice and PostnCre/eGFP mice). Mice were housed in specific 
pathogen–free animal facilities at the Johns Hopkins University. Experiments were 
conducted on 6–10-wk-old age-matched male mice (EAM) or 8–16-wk-old age-matched 
male mice (MI) in compliance with the Animal Welfare Act and the principles set forth in 
the Guide for the Care and Use of Laboratory Animals. All methods and protocols were 
approved by the Animal Care and Use Committee of Johns Hopkins University.
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EAM mouse model
To induce EAM, mice on BALB/c background received subcutaneous immunizations on 
days 0 and 7 of 125 μg per mouse of myosin heavy chain α peptide (MyHCα614–629) 
(AcSLKLMATLFSTYASAD; commercially synthesized by fMOC chemistry and purified to 
a minimum of 90 % by HPLC, Genscript) [74] emulsified in CFA (Sigma-Aldrich) 
supplemented to 5 mg/mL heat-killed Mycobacterium tuberculosis strain H37Ra (Difco). On 
day 0, mice also received 500 ng pertussis toxins intraperitoneally (List Biologicals) [75]. 
Mouse hearts were harvested on days 0, 14 or 21 for flow cytometry analysis.
MI mouse model
To induce MI, mice were subjected to permanent ligation of the left anterior descending 
coronary artery or to a sham operation without ligation [76]. Briefly, mice were anesthetized 
with 3.5 % isoflurane (Baxter), endotracheally intubated, and mechanically ventilated with 
1.5 % isoflurane (Baxter) throughout the operation process via small animal ventilator 
(Model 845, Harvard Apparatus). Pre-operational analgesics (0.05 mg/kg Buprenorphine, 
Reckitt Benckiser) and paralytics (1 mg/kg Succinylcholine, Henry Schein) were 
administered prior to operation. Mice were subjected to thoracotomy typically around the 
3rd or 4th intercostal space. An 8–0 polyethylene suture was advanced sub-epicardially and 
perpendicular to the left anterior descending coronary artery. For permanent occlusion, a 
ligature was tightened around the artery, and could be visualized by myocardial bleaching 
and loss of motion below the occlusion. The chest and skin were closed with a 6–0 nylon 
suture followed by removal of air from the thorax via a pleural catheter. The procedure was 
performed by the same surgeon blinded to genotypes. Mice that died during recovery from 
anesthesia were excluded. Sham-operated animals underwent the same procedure without 
coronary artery ligation. Mice were sacrificed, and hearts were harvested on days 2 or 4 
post-MI for flow cytometry analysis, or on days 7 or 28 post-MI to assess cardiac 
remodeling outcomes.
Infarct size evaluation
Heart tissues were fixed in SafeFix solution (Thermo-Fisher Scientific), embedded in 
paraffin, and cut into 5-μm-thick sections. Hematoxylin and eosin (H&E) and Masson’s 
trichrome staining (HistoServ) were performed on paraffin-embedded sections to determine 
the infarct size. Three sections were used to calculate the infarct size, i.e. a section right 
below the ligation site (Section A), a section near the apex (Section C) and Section B at a 
midpoint of sections A and C. The infarct size was calculated as the total infarct 
circumference of all three sections divided by the total left ventricle circumference of all 
three sections [77].
Processing human cardiac samples
Sample weights ranged between 80 mg and 300 mg. Specimens were cut into fragments of 
approximately 2 mm3. Fragments were placed in GentleMACS C Tubes (Miltenyi Biotec) in 
5 mL of enzymatic digestion buffer composed of 5 mL of Hank’s Balanced Salt Solution 
[HBSS] (Corning) with 600 U/mL of Collagenase II and 60 U/mL of DNase I (Worthington 
Biochemical Corporation) and mechanically dissociated with GentleMACS (Miltenyi 
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Biotec). Samples were digested for 30 min at 37°C with shaking, and mechanically 
dissociated with GentleMACS (Miltenyi Biotec) again. Cell suspensions were filtered 
through 40 μm cell strainers (Bioland Scientific). Finally, cells were washed and 
resuspended in PBS with cell concentration adjusted to 106–107 cells/200 μL of PBS for 
antibody staining.
Processing mouse cardiac cells
Mouse cardiac cells were isolated by perfusing the mouse hearts for 3 min with PBS and 
digested in GentleMACS C Tubes (Miltenyi Biotec) with 5 mL of enzymatic digestion 
buffer composed of 5 mL HBSS (Corning) supplemented with 3,000 U/mL Collagenase II 
and 90 U/mL DNase I (Worthington Biochemical Corporation). Samples were digested for 
30 min at 37°C with shaking. Mechanical dissociation with GentleMACS (Miltenyi Biotec) 
was performed before and after the 30-minute incubation [78]. Cells were filtered through a 
40 μm cell strainer (Bioland Scientific), washed and resuspended in PBS. For intracellular 
cytokine staining, cells were stimulated in vitro for 4 h with 50 ng/mL Phorbol 12-myristate 
13-acetate (PMA), 750 ng/mL ionomycin (Sigma-Aldrich), Golgi Stop, and Golgi Plug 
(BD) before staining. Cells were washed in PBS prior to antibody staining. For isolation of 
primary adult mouse Sca-1+ cardiac fibroblasts, processed cardiac cells were subjected to 
Histopaque1119 gradient (Sigma-Aldrich) to remove dead cells and debris according to the 
manufacturer’s instructions. Leukocytes and endothelial cells were removed by CD45 and 
CD31 MACS paramagnetic depletion (Miltenyi Biotec) and Sca-1+ cells were isolated using 
Sca-1 MACS paramagnetic positive selection following manufacturer’s instructions. Cells 
were washed and seeded on culture flasks.
Processing mouse splenocytes
Single-cell suspension of splenocytes was made from the mouse spleen by mechanical 
dissociation followed by the lysis of red blood cells with ACK lysis buffer (Quality 
Biologicals), filtered through a 70 μm cell strainer (Bioland Scientific), washed and 
resuspended in PBS. Splenocytes were used for compensation controls for flow cytometry 
analysis.
Human primary cardiac fibroblasts
We acquired human primary cardiac fibroblasts from Cell Applications, Inc (San Diego, 
CA). Cells were thawed at 37°C immediately after taken out from liquid nitrogen (−196°C), 
washed and seeded on uncoated culture flasks in human cardiac fibrob-lasts growth medium 
according to manufacturer’s instructions (Cell Applications). Cells were passaged every 2–3 
days. For stimulation, cells were seeded on 6-well plates and stimulated with 50 ng/mL of 
recombinant human IL-17A (Peprotech) for the Th17 conditions or 100 ng/mL of 
recombinant human IL-13 (Peprotech) for the Th2 conditions for three days. For flow 
cytometry, cells were detached using 0.05% trypsin-EDTA (Quality Biologicals) and washed 
in PBS prior to antibody staining. For cytokine repolarization experiments, cell culture 
supernatant was harvested, and cells were washed with PBS and cultured for another three 
days with new stimuli according to experiment design. Unstimulated cells were used as 
controls. Supernatant was collected upon harvest and stored at −80°C. Secreted cytokine 
levels were measured by quantitative sandwich ELISA.
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Mouse primary Sca-1+ cardiac fibroblasts
Sca-1+ cardiac cells were isolated using MACS sorting beads as described above, and then 
seeded on culture flasks (Corning) in adult mouse cardiac fibroblast culture medium 
(DMEM with 4.5 g/L glucose, 2 mM L-glutamine, 1 mM sodium pyruvate, 25 mM Hepes, 
100 U/mL penicillin G, 100 μg/mL streptomycin, 250 ng/mL amphotericin B, and 20 % 
FBS). Cells were passaged every 3–4 days. For stimulation, cells were seeded on 24-well 
plates and stimulated with 50 ng/mL of recombinant mouse IL-17A, 100 ng/mL of 
recombinant mouse IL-13, 50 ng/mL of recombinant mouse IFN-γ, 20 ng/mL of 
recombinant mouse TNF-α, or combinations of two cytokines for three days based on the 
experiment designs. All recombinant mouse cytokines were purchased from Peprotech 
(Rocky Hill, NJ). For flow cytometry, cells were detached using 0.05% trypsin-EDTA 
(Quality Biologicals) and washed in PBS prior to antibody staining. For cytokine 
repolarization experiments, cell culture super-natant was harvested, and cells were washed 
with PBS and cultured for another three days with new stimuli according to the experiment 
designs. Unstimulated cells were used as controls. Supernatant was collected upon harvest 
and stored at −80°C. Secreted cytokine levels were measured by quantitative sandwich 
ELISA.
Flow cytometry and fluorescence activated cell sorting (FACS)
Cell viability was determined by LIVE/DEAD staining according to the manufacturer’s 
instructions (Life Technologies). Prior to surface immunostaining, samples were incubated 
with unconjugated Fc Receptor Binding Inhibitor (eBioscience). Cell surface markers were 
then stained with antibodies conjugated with fluorochromes (eBiosciences, BD and 
BioLegend). For intracellular cytokine staining, cells were fixed in CytoFix/CytoPerm (BD) 
and stained with antibodies against cytokines in Perm/Wash Buffer (BD). For phosphor flow 
of signaling molecules, cells were fixed in CytoFix/CytoPerm (BD) and stained with 
antibodies against signaling molecules in BD PhosFlow Perm/Wash Buffer (BD). Samples 
were acquired on the LSR II or LSR Fortessa cytometer running FACS Diva 6 (BD). For 
FACS isolation, single cell suspension from mouse hearts was further purified with a 
Histopaque-1119 gradient separation (Sigma-Aldrich) to eliminate dead cells and debris. 
Cells were then stained with antibodies conjugated with fluorochromes (eBioscience, BD, 
and BioLegend) and sorted with FACSAria Ilu Cell Sorter (BD). Antibodies used are listed 
in Supporting Information Table 1. Data were analyzed with Flow Jo 10.4 (Tree Star) and 
the t-distributed stochastic neighbor-embedding (t-SNE) algorithm embedded in FlowJo 
10.4.
Immunoblot
We carried out immunoblot assays as previously described [79]. In brief, we cultured mouse 
primary Sca-1+ cardiac fibroblasts under the Th17 conditions (50 ng/mL of IL-17A and 20 
ng/mL TNF-α) or the Th2 conditions (100 ng/mL of IL-13) for the duration indicated, 
harvested, and lysed on ice by lysis buffer (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1 % 
NP-40 and 0.5 % sodium deoxy cholate, 1x complete protease inhibitor cocktail (Roche 
Applied Science) for 30 min. Subcellular fractionation was performed by differential 
centrifugation as previously described [80]. The lysates or nuclear fractions were centrifuged 
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at 10 000× g at 4°C for 10 min, and the supernatant was separated by SDS-PAGE under 
reducing and denaturing conditions. The resolved protein bands were transferred onto 
nitrocellulose membranes and probed by the Super Signaling system (Thermo-Fisher 
Scientific) according to the manufacturer’s instructions and imaged using FluorChem E 
System (Protein Simple). Antibodies used are listed in Supporting Information Table 1.
ELISA
Supernatant collected from cell culture was stored at −80°C before analysis. Protein levels of 
secreted GM-CSF and CCL11 were determined by quantitative sandwich ELISA according 
to manufacturer’s recommended protocols (R&D Systems).
Quantitative PCR
Total RNA from cardiac tissues, FACS isolated cells or cultured cells was extracted in 
TRIzol (Invitrogen) and quantitated. Single-stranded cDNA was synthesized with the High 
Capacity cDNA Reverse Transcription kit (Thermo-Fisher Scientific). Expression levels of 
mouse genes were detected using quantitative real-time PCR with iQ SYBR Green Master 
mix (Bio-Rad Laboratories) and acquired on the MyiQ2 thermocycler with iQ5 software 
(Bio-Rad Laboratories). Quantitative real-time TaqMan PCR was performed for human 
genes and acquired on the MyiQ2 thermocycler with iQ5 software (Bio-Rad Laboratories). 
Data were analyzed by the 2− Ct method [81], normalizing threshold cycles first to Gapdh 
(for mouse gene analysis) or HPRT1 (for human gene analysis) expression and then to 
biological controls. The following TaqMan primers for human genes (Applied Biosystems) 
were used: CSF2 (Hs00929873 m1), CCL2 (Hs00234140 m1), CCL11 (Hs00237013 m1), 
CCL24 (Hs00171082 m1), CCL26 (Hs00171146 m1) and the housekeeping gene HPRT1 
(Hs02800695 m1). Mouse primers used are listed in Supporting Information Table 2.
Statistics
Two groups with normally distributed data were analyzed using Student’s t-test. Mann-
Whitney test was used to analyze discontinuous parametric data. Multiple group analysis 
was performed by one-way ANOVA followed by Tukey’s multiple comparisons test for 
continuous variables. Survival analysis was performed by the Kaplan-Meier method and 
compared by Log-rank (Mantel-Cox) test. Calculations were performed in Prism 6 (Graph 
Pad Software). P-values of 0.05 or less were considered statistically significant and are 
denoted by asterisks: *p < 0.05; **p <0.01; ***p < 0.001.
Study approval
Human study protocol was approved by the Committee for the Protection of Human 
Subjects at University of Texas Health Science Centre at Houston with IRB # HSC-MS-05–
0074. All animal studies were performed with the approval of the Institutional Animal Care 
and Use Committee at Johns Hopkins University School of Medicine. These investigations 
followed the Guide for the Care and Use of Laboratory Animals, published by the National 
Institutes of Health.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations:
CCL11 C-C motif chemokine ligand 11 (eotaxin 1)
CCL2 C-C motif chemokine ligand 2
CCL24 C-C motif chemokine ligand 24 (eotaxin 2)
CCL26 C-C motif chemokine ligand 26 (eotaxin 3)
CF Cardiac fibroblast
Csf2 GM-CSF gene name
CXCL10 C-X-C motif chemokine ligand 10
DCMi Inflammatory dilated cardiomyopathy
DDR2 Discoidin domain receptor 2
EAM Experimental autoimmune myocarditis
Erk1/2 Extracellular signal-regulated kinase 1/2
GM-CSF Granulocyte macrophage colony-stimulating factor
IFN-γ Interferon gamma
IL-13 Interleukin 13
IL-17A Interleukin 17A
IL17RA IL-17A receptor A
MAPK Mitogen-activated protein kinase
MI Myocardial infarction
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NFAT2 Nuclear factor of activated T-cells 2
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
PDGFRα Platelet-derived growth factor receptor alpha (CD140α)
PMA Phorbol 12-myristate 13-acetate
Postn Periostin gene name
Sca-1 Stem cell antigen-1
Stat3 Signal transducer and activator of transcription 3
Stat6 Signal transducer and activator of transcription 6
Th17 T helper type 17
Th2 T helper type 2
TNF-α Tumor necrosis factor alpha
t-SNE t-distributed stochastic neighbor embedding
WT Wild type
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Figure 1. 
Sca-1+ cardiac fibroblasts are potent GM-CSF-producers during cardiac inflammation. 
Cardiac fibroblasts were harvested from wild type BALB/c mice with EAM on days 0, 14 or 
21 for flow cytometry analysis. (A) Representative flow cytometry plots depict gating 
strategies for cardiac fibroblast subsets. (B) Flow cytometric quantification of the numbers 
of cardiac fibroblast subsets per mg cardiac tissue at different time points after EAM 
induction. (n = 4 for EAM day 0 group; n = 6 for EAM day 14 group; n = 7 for EAM day 21 
group; CF cardiac fibroblast) (C) Demonstration of cell number changes in cardiac fibroblast 
subsets after EAM induction. (D) Representative flow cytometry= plots showing GM-CSF 
staining of cardiac fibroblast subsets on day 21 of EAM. (E and F) Representative t-SNE 
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clustering plots of (E) cardiac fibroblast subsets and GM-CSF-positive cardiac fibroblasts or 
(F) all GM-CSF-positive cardiac cells on day 21 of EAM using t-SNE dimensionality 
reduction algorithm plugin in FlowJo 10.4.2 (FlowJo, LLC). (G) Relative frequency of 
different cell populations out of all GM-CSF-positive cells in the hearts on day 21 of EAM. 
(H) Frequency and number of GM-CSF-positive Sca-1+ cardiac fibroblasts per mg cardiac 
tissue in immunized mice (n = 9) versus mock-immunized mice (n = 10) on day 21 of EAM. 
(I) Frequency and number of GM-CSF-positive Sca-1+ cardiac fibroblasts per mg cardiac 
tissue in immunized WT mice and Il17ra−/− mice on day 21 of EAM (n = 10 per group). 
Data are representative of three independent experiments (A–I). Groups were compared 
using one-way ANOVA followed by Tukey’s post-test (B) or Student’s t-test (H–I). *p < 
0.05; **p < 0.01; ***p < 0.001.
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Figure 2. 
Sca-1+ cardiac fibroblasts are potent producers of different cytokines and chemokines and 
are plastic in response to environment changes. (A) The mRNA expression levels of Csf2, 
Ccl2, Cxcl10, Ccl11 and Postn in na¨ıve mouse heart homogenates, EAM day 21 mouse 
heart homogenates and FACS-sorted Sca-1+ and Sca-1− cardiac fibroblasts from EAM day 
21 mouse hearts (n =5 per group; n.d. not detected; WH = whole heart homogenate). 
Expression levels were analyzed by qPCR (2− ΔΔ Ct values relative to Gapdh expression 
levels and=na¨ıve whole heart transcripts). (B) The mRNA expression levels of Csf2, Ccl2, 
Cxcl10 and Ccl11 in in vitro cultured Sca-1+ cardiac fibroblasts stimulated with IL-17A, 
IL-13, IFN-γ, or unstimulated (control). Expression levels were analyzed by qPCR (2−ΔΔCt 
values relative to Gapdh expression levels and unstimulated controls). (C) Representative 
histogram of mCherry (CCL2) expression in cultured Sca-1+ cardiac fibroblasts under Th17 
conditions or unstimulated. (D) Schematic of the experiment procedures for all data showing 
in E–F. (E) Expression levels of Ccl2, Csf2 and Ccl11 mRNA in cells harvested on day 3 or 
day 6. Expression levels were analyzed by qPCR (2−͉ ΔΔCt values relative to Gapdh 
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expression levels and unstimulated controls). (F) Protein concentrations of secreted CCL11 
and GM-CSF in the culture supernatant harvested on day 3 or day 6 were measured by 
quantitative sandwich ELISA. Data are shown as mean + SD of five mice per group (A) or of 
technical triplicates (B, E–F). Data are representative of three indepen dent experiments (A–
F). Groups were compared using one-way ANOVA followed by Tukey’s post-test (A, E–F) 
or Student’s t-test (B). **p < 0.01; ***p < 0.001.
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Figure 3. 
IL-17A induces GM-CSF production in Sca-1+ cardiac fibroblasts through synergistic 
activation of NF-κB and NFAT2. (A–C) Sca-1+ cardiac fibroblasts were MACS-sorted from 
naïve WT mouse hearts and cultured under Th17 conditions (IL-17A TNF-α), Th2 
conditions (IL-13) or unstimulated (control) for two days (A) or for multiple time points (B–
C). (A) Representative flow cytometry plots showing phosphorylated p-65 (pp65)-positive 
and/or NFAT2-positive Sca-1+ cardiac fibroblasts and representative histogram showing 
their GM-CSF expression. (B) Immunoblots showing the detection of total or 
phosphorylated Stat6, Stat3, p65 and Erk1/2 in whole cell lysate. (C) Immunoblots showing 
the detection of p65, Stat6, Parp1 (nuclear positive control) and pro-Caspase 3 (nuclear 
negative control) in the nuclear fraction of Sca-1 cardiac fibroblasts with/without 
stimulation. Data are representative of three independent experiments (A–C).
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Figure 4. 
IL-17A signaling ablation leads to less GM-CSF-positive Sca-1+ cardiac fibroblasts and 
protects mice from post-MI heart failure and death. (A) Representative flow cytometry plots 
showing GM-CSF- and CCL2-positive Sca-1+ cardiac fibroblasts in infarcted and sham-
operated mouse hearts on day 2 post-MI. Cells were pre-gated on viable 
CD45−CD31−Sca-1+ cardiac cells. (B) Flow cytometric quantification of GM-CSF+, CCL2+ 
and GM-CSF+CCL2+ Sca-1+ cardiac fibroblasts per mg cardiac tissue of infarcted or sham-
operated WT mice (n =3 per group). (C) Kaplan-Meier survival curve of WT mice (n = 8) 
and Il17ra−/− mice (n = 17) on day 28 post-MI. (D) images Representative of Masson’s 
trichrome stained histology slides of the cross-sections at the middle of the hearts from WT 
and Il17ra−/− mice showing the expansion of the infarct area and the dilation of the left 
ventricles on day 28 post-MI. (Scalebar, 1mm) (E) Calculated total infarct sizes of WT mice 
(n = 6) and Il17ra−/− mice (n 14) on day 28 post-MI. (F) Flow cytometric quantification of 
GM-CSF-positive Sca-1+ cardiac fibroblasts per mg cardiac tissue in WT and Il17ra
−/−
=mice on day 2 post-MI (n = 5 per group). Data are representative of three independent 
experiments (A–F). Groups were compared using Student’s t-test (B, E–F) or Long-rank 
(Mantel-Cox) test (C). *p < 0.05; **p < 0.01.
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Figure 5. 
GM-CSF-positive Sca-1+ cardiac fibroblasts express periostin post-MI and specific IL-17RA 
ablation in periostin+ cardiac fibroblasts protects mice from post-MI heart failure and death. 
(A) Representative flow cytometry plots showing Sca-1+ and GM-CSF+Sca-1+ cardiac 
fibroblasts and representative histograms of their GFP (periostin) expression in infarcted WT 
mouse hearts (gray shadowed), sham (black dashed line) and infarcted (black solid line) 
PostnCre/eGFP mouse hearts on day 2 post-MI. Cells were pre-gated on viable 
CD45−CD31−CD29+ cells. (B) Representative images of Masson’s trichrome stained 
histology slides of the cross-sections at the middle of the hearts from sham and infarcted 
PostnCre, infarcted Il17rafl/fl and infarcted PostnCreIl17rafl/fl mice on day 7 post-MI 
(PostnCreIl17rafl/fl mice were labeled in this Figure as PostnIL−17RAKO) showing the 
expansion of the infarct area and the dilation of the left ventricle of the infarcted mouse 
hearts. (Scalebar, 1mm) (C) Calculated total infarct sizes of infarcted Il17rafl/fl mice (n = 8) 
and PostnCreIl17rafl/fl mice (n =9) on day 7 post-MI. (D) Kaplan-Meier survival analysis of 
infarcted Il17rafl/fl mice (n = 31) and PostnCreIl17rafl/fl mice (n = 11) on day 28 post-MI. (E) 
Flow cytometric quantification of GM-CSF-positive Sca-1+ cardiac fibroblasts per mg 
cardiac tissue in PostnCre and PostnCreIl17rafl/fl mice on day 4 post-MI (n = 3 per group). (F-
G) Flow cytometric quantification of the frequency (F) and the number (G) of Ly6Chi 
monocytes per mg cardiac tissue in PostnCre and PostnCreIl17rafl/fl mice on day 4 post-MI (n 
= 3 per group). “PostnIL−17RAKO” stands for “PostnCreIl17rafl/fl mice”. “CFs” stands for 
“cardiac fibroblasts”. Data are representative of three independent = experiments (A–G). 
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Groups were compared using Student’s t-test (C, E–G) or Long-rank (Mantel-Cox) test (D). 
*p < 0.05, **p < 0.01.
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Figure 6. 
GM-CSF-expressing cardiac fibroblast subset was found in human cardiac fibroblasts and 
exhibits similar functional plasticity. (A) Representative flow cytometry plots showing the 
gating strategies for cultured human primary cardiac fibroblasts. (B) Representative t-SNE 
clustering plots of three human cardiac fibroblast subsets using t-SNE dimensionality 
reduction algorithm plugin in FlowJo 10.4.2 (FlowJo, LLC). (C) Representative expression 
heat maps of cell surface markers, CD29, CD73, CD105, CD90, PDGFRα, cKit, DDR2 and 
GM-CSF expression in human cardiac fibroblasts using t-SNE dimensionality reduction 
algorithm plugin in FlowJo 10.4.2 (FlowJo, LLC). (D–E) The mRNA expression levels of 
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CCL2, CSF2, CCL11, CCL24 and CCL26 of human primary cardiac fibroblasts cultured 
under IL-17A, IL-13 or unstimulated (control) for three days (D) or washed and recultured 
again with/without change of stimuli for another three days (E). The mRNA expression 
levels were analyzed by qPCR (2−ΔΔ Ct values relative to HPRT1 expression levels and 
unstimulated controls). Data are shown as mean SD of technical triplicates and are 
representative of three independent experiments (D–E). Groups were compared using 
Student’s t test (D) or +using one-way ANOVA followed by Tukey’s post-test (E). **p < 
0.01; ***p < 0.001.
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Figure 7. 
Human cardiac fibroblasts from heart failure patients produce GM-CSF and CCL2. (A) 
Representative flow cytometry plots of the concatenated sample showing gating strategy for 
human CD45−CD31−CD29+PDGFRα+ cardiac fibroblasts and flow cytometry plots 
showing GMCSF and CCL2 expressions for PDGFRα+ and PDGFRα− cardiac fibroblasts 
from the heart biopsies of myocarditis or ischemic heart failure patients. (B) Representative 
flow cytometry plots showing GM-CSF and CCL2 expression by PDGFRα+ cardiac 
fibroblasts from heart biopsies of five myocarditis heart failure patients. (C) Representative 
flow cytometry plots showing GM-CSF and CCL2 expression by PDGFRα+ cardiac 
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fibroblasts from heart biopsies of five ischemic heart failure patients. Data are from 5 
myocarditis heart failure patients and 5 ischemic heart failure patients.
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